US5120722A
(en)
|
1984-02-08 |
1992-06-09 |
Hoffmann-La Roche Inc. |
Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
|
US4857518A
(en)
|
1984-10-04 |
1989-08-15 |
Wisconsin Alumni Research Foundation |
Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
|
US4717721A
(en)
|
1985-05-30 |
1988-01-05 |
Howard W. Bremer |
Sidechain homo-vitamin D compounds with preferential anti-cancer activity
|
JPH07100685B2
(ja)
|
1985-08-02 |
1995-11-01 |
レオ・ファ−マシュ−ティカル・プロダクツ・リミテッド・エイ/エス(レ−ベンス・ケミスケ・ファブリック・プロデュクチオンスアクチ−セルスカブ) |
新規ビタミンd類似体
|
US5145846A
(en)
|
1988-01-20 |
1992-09-08 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
US4851401A
(en)
|
1988-07-14 |
1989-07-25 |
Wisconsin Alumni Research Foundation |
Novel cyclopentano-vitamin D analogs
|
CA1333616C
(en)
|
1989-03-09 |
1994-12-20 |
Hector F. Deluca |
19-nor-vitamin d compounds
|
GB8915770D0
(en)
|
1989-07-10 |
1989-08-31 |
Leo Pharm Prod Ltd |
Chemical compounds
|
US4966898A
(en)
|
1989-08-15 |
1990-10-30 |
Merrell Dow Pharmaceuticals Inc. |
4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
|
DE4021433A1
(de)
|
1990-07-04 |
1992-01-09 |
Schering Ag |
Antiandrogene mit steroid(3,2-c)pyrazol-struktur
|
DE4101953A1
(de)
|
1991-01-19 |
1992-07-23 |
Schering Ag |
23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
|
DE4141746A1
(de)
|
1991-12-13 |
1993-06-17 |
Schering Ag |
20-methyl-substituierte vitamin d-derivate
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
DK0633893T3
(da)
|
1992-03-31 |
2000-04-17 |
Btg Int Ltd |
17-Substituerede steroider, der er nyttige ved cancerbehandling
|
US5547947A
(en)
|
1993-03-11 |
1996-08-20 |
Hoffmann-La Roche Inc. |
Methods of treatment
|
DK0721461T3
(da)
|
1993-09-30 |
1999-09-20 |
Btg Int Ltd |
Syntese af 17-(3-pyridyl)-steroider
|
US5688977A
(en)
|
1996-02-29 |
1997-11-18 |
Napro Biotherapeutics, Inc. |
Method for docetaxel synthesis
|
ATE196844T1
(de)
|
1996-05-22 |
2000-10-15 |
Protarga Inc |
Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
|
US5919815A
(en)
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
GB9622590D0
(en)
|
1996-10-30 |
1997-01-08 |
Leo Pharm Prod Ltd |
Chemical compounds
|
US20020128240A1
(en)
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
US20050233958A1
(en)
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
US6087350A
(en)
|
1997-08-29 |
2000-07-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
|
AU762481C
(en)
|
1998-03-27 |
2004-08-19 |
Oregon Health Sciences University |
Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
|
US20030083231A1
(en)
|
1998-11-24 |
2003-05-01 |
Ahlem Clarence N. |
Blood cell deficiency treatment method
|
JP2002533416A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール & カンパニー |
新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−2インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
|
WO2001064251A2
(en)
|
2000-03-02 |
2001-09-07 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Combination chemotherapy
|
WO2001081364A1
(fr)
|
2000-04-24 |
2001-11-01 |
Kyowa Hakko Kogyo Co., Ltd. |
Derives d'estra-1,3,5(10)-triene
|
AU2001261474B2
(en)
|
2000-05-15 |
2006-03-09 |
Celgene Corporation |
Compositions and methods for the treatment of cancer
|
EP1676577A1
(en)
|
2000-05-15 |
2006-07-05 |
Celgene Corporation |
Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
|
AU7542301A
(en)
|
2000-06-09 |
2001-12-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
AU2000260772A1
(en)
|
2000-07-05 |
2002-01-14 |
Bryan Muehlberger |
Systems and methods of facilitating electronic payment transactions
|
US6656942B2
(en)
|
2000-10-17 |
2003-12-02 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
DE10061137B4
(de)
|
2000-12-07 |
2016-10-06 |
Takeda Gmbh |
Neue pharmazeutische Zubereitung
|
AU2002219472A1
(en)
|
2001-01-02 |
2002-07-16 |
Elisabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
WO2002085354A1
(en)
|
2001-04-18 |
2002-10-31 |
Euro-Celtique S.A. |
Spiroindene and spiroindane compounds
|
ES2312616T3
(es)
|
2001-04-18 |
2009-03-01 |
Euro-Celtique S.A. |
Compuestos de bencimidazolona.
|
US6867222B2
(en)
|
2001-04-18 |
2005-03-15 |
Euro-Celtique, S.A. |
Nociceptin analogs
|
ATE403429T1
(de)
|
2001-04-18 |
2008-08-15 |
Euro Celtique Sa |
Spiropyrazol-verbindungen
|
CA2445922A1
(en)
|
2001-05-10 |
2002-11-21 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
WO2004016753A2
(en)
|
2002-08-15 |
2004-02-26 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
WO2002102783A1
(en)
|
2001-06-19 |
2002-12-27 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6740641B2
(en)
|
2001-07-27 |
2004-05-25 |
Euro-Celtique, S.A. |
Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
|
US7186723B2
(en)
|
2001-08-30 |
2007-03-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
EP1423381B1
(en)
|
2001-09-06 |
2007-01-03 |
Schering Corporation |
17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
AU2002363429B2
(en)
|
2001-11-07 |
2008-05-08 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
AU2002357053B2
(en)
|
2001-12-06 |
2008-05-15 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
ES2345044T3
(es)
|
2002-02-01 |
2010-09-14 |
Euro-Celtique S.A. |
2-piperazin-piridinas utiles para tratar el dolor.
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
US6974818B2
(en)
|
2002-03-01 |
2005-12-13 |
Euro-Celtique S.A. |
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
|
US20050159361A1
(en)
|
2002-03-11 |
2005-07-21 |
Takahito Hara |
Remedies for sex hormone-dependent disease
|
US7273869B2
(en)
|
2002-04-08 |
2007-09-25 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
EP1927858B1
(en)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Conformationally constrained peptides that bind the ORL-1 receptor
|
US7125888B2
(en)
|
2002-05-02 |
2006-10-24 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
EP1515949B1
(en)
|
2002-06-14 |
2007-03-14 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
WO2004002983A2
(en)
|
2002-06-28 |
2004-01-08 |
Euro-Celtique, S.A. |
Therapeutic piperazine derivatives useful for treating pain
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
EP2298315A1
(en)
|
2002-08-28 |
2011-03-23 |
Harbor BioSciences, Inc. |
Therapeutic treatment methods
|
US20050101581A1
(en)
|
2002-08-28 |
2005-05-12 |
Reading Christopher L. |
Therapeutic treatment methods 2
|
US7157462B2
(en)
|
2002-09-24 |
2007-01-02 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
US8987240B2
(en)
|
2002-10-23 |
2015-03-24 |
Pantarhei Bioscience B.V. |
Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
|
CA2503715A1
(en)
|
2002-10-30 |
2004-05-21 |
Merck & Co., Inc. |
Kinase inhibitors
|
US7202259B2
(en)
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
MXPA05006485A
(es)
|
2002-12-17 |
2005-08-26 |
Schering Corp |
Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno.
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
WO2004062620A2
(en)
|
2003-01-13 |
2004-07-29 |
Cedars-Sinai Medical Center |
Paricalcitol as a chemotherapeutic agent
|
TWI330079B
(en)
|
2003-01-15 |
2010-09-11 |
Synta Pharmaceuticals Corp |
Treatment for cancers
|
CA2524737A1
(en)
|
2003-05-06 |
2005-02-24 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
US20050020546A1
(en)
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
MY142655A
(en)
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
EA009480B1
(ru)
|
2003-07-24 |
2008-02-28 |
Еуро-Селтик С. А. |
Гетероарил-тетрагидропиридины и их применение для лечения или профилактики боли
|
PL1867644T3
(pl)
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
|
US7071333B2
(en)
|
2003-07-30 |
2006-07-04 |
Bristol-Myers Squibb Company |
Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
|
DE602004025244D1
(de)
|
2003-08-01 |
2010-03-11 |
Euro Celtique Sa |
Zur behandlung von schmerzen geeignete therapeutische mittel
|
CA2535366A1
(en)
|
2003-08-27 |
2005-03-10 |
Merck Frosst Canada & Co. |
Cathepsin inhibitors
|
CN1856489A
(zh)
|
2003-09-22 |
2006-11-01 |
欧洲凯尔特公司 |
用于治疗疼痛的苯甲酰胺化合物
|
DE602004017481D1
(de)
|
2003-09-22 |
2008-12-11 |
Euro Celtique Sa |
Zur behandlung von schmerzen geeignete therapeutische mittel
|
ATE369862T1
(de)
|
2003-10-17 |
2007-09-15 |
4 Aza Ip Nv |
Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie
|
WO2005107801A2
(en)
|
2004-04-29 |
2005-11-17 |
The Regents Of The University Of Colorado |
Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
|
US20060003950A1
(en)
|
2004-06-30 |
2006-01-05 |
Bone Care International, Inc. |
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
US20060030608A1
(en)
|
2004-08-04 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anti aromatase compounds pharmaceutical compositions and uses thereof
|
GB0418900D0
(en)
|
2004-08-24 |
2004-09-29 |
Btg Int Ltd |
Novel salt forms
|
CA2579732C
(en)
|
2004-09-10 |
2014-08-12 |
Nitec Pharma Ag |
Tablets with site time-controlled gastrointestinal release of active ingredient
|
AR051597A1
(es)
|
2004-11-01 |
2007-01-24 |
Merck & Co Inc |
Moduladores de los receptores de estrogeno
|
EP1674479A1
(en)
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
WO2006081152A2
(en)
|
2005-01-24 |
2006-08-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
WO2006116716A2
(en)
|
2005-04-27 |
2006-11-02 |
University Of Florida |
Materials and methods for enhanced degradation of mutant proteins associated with human disease
|
JP2008539238A
(ja)
|
2005-04-28 |
2008-11-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド |
治療用二機能性化合物
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
CA2616537A1
(en)
|
2005-07-27 |
2007-02-01 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
CA2647545C
(en)
|
2006-04-03 |
2016-02-23 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
|
EP2035043A2
(en)
|
2006-06-02 |
2009-03-18 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Rna nanoparticles and nanotubes
|
US20080004286A1
(en)
|
2006-06-30 |
2008-01-03 |
Schering Corporation |
Method of Using Substituted Piperidines that Increase P53 Activity
|
BRPI0713119A2
(pt)
|
2006-06-30 |
2012-04-17 |
Schering Corp |
piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
US20080051375A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
WO2008024484A1
(en)
|
2006-08-25 |
2008-02-28 |
Cougar Biotechnology, Inc. |
Methods and compositions for treating cancer
|
EP2081964A4
(en)
|
2006-10-12 |
2012-07-11 |
Univ Johns Hopkins |
ALGINATE AND ALGINATLYASE COMPOSITIONS AND USE METHOD
|
US20100168228A1
(en)
|
2006-10-13 |
2010-07-01 |
Reliance Life Sciences Pvt. Ltd. |
Novel chemotherapeutic agents against inflammation and cancer
|
SI2805945T1
(sl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
WO2008109740A2
(en)
|
2007-03-06 |
2008-09-12 |
Colby Pharmaceutical Company |
Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
|
WO2009009132A1
(en)
|
2007-07-12 |
2009-01-15 |
Cougar Biotechnology, Inc. |
Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
|
RU2495035C2
(ru)
|
2008-01-08 |
2013-10-10 |
Мерк Шарп Энд Домэ Лтд |
Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида
|
CL2009000780A1
(es)
|
2008-03-31 |
2010-01-15 |
Genentech Inc |
Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
|
CN104945309B
(zh)
|
2008-05-07 |
2019-06-04 |
卡尔迪奥克斯尔制药公司 |
作为硝酰基供体的新亚硝基化合物及其用途
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
WO2012106514A2
(en)
|
2011-02-03 |
2012-08-09 |
Pop Test Cortisol Llc |
System and method for diagnosis and treatment
|
US9314473B2
(en)
|
2011-02-03 |
2016-04-19 |
Pop Test Oncology Limited Liability Company |
System and method for diagnosis and treatment
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
WO2014150000A1
(en)
|
2013-03-21 |
2014-09-25 |
Isp Investments Inc. |
Diacetylene film sensitized with photoinitiator and applications of the film
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
US9987275B2
(en)
|
2014-04-23 |
2018-06-05 |
The Brigham And Women's Hospital, Inc. |
Targeting PARP1 for treatment of TSC and cancers
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
EP3230472A4
(en)
|
2014-12-08 |
2018-06-13 |
Myriad Genetics, Inc. |
Methods and materials for predicting response to niraparib
|
WO2017023694A1
(en)
|
2015-08-03 |
2017-02-09 |
Pop Test Oncology Llc |
Pharmaceutical compositions and methods
|
CA3031705A1
(en)
|
2016-07-29 |
2018-02-01 |
Janssen Pharmaceutica Nv |
Treatment of prostate cancer with niraparib
|
WO2018067520A2
(en)
|
2016-10-04 |
2018-04-12 |
Pop Test Oncology Llc |
Therapeutic agents and methods:
|
US11702443B2
(en)
|
2016-10-04 |
2023-07-18 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
JOP20190244A1
(ar)
|
2017-04-13 |
2019-10-13 |
Janssen Pharmaceutica Nv |
تركيبة علاجية لسرطان البروستاتا
|
BR112020007090A2
(pt)
|
2017-10-11 |
2020-09-24 |
Janssen Oncology, Inc. |
métodos de tratamento de câncer de próstata mediante a administração de acetato de abiraterona mais prednisona com terapia de supressão androgênica
|